



ecmc

Experimental
Cancer
Medicine
Centres

One-of-a-kind
research network.

ECMC Programme Office

ecmc

Jointly
funded by:




NIHR | National Institute
for Health Research



A Research Network like no other

Advancing experimental cancer medicine


- A unique network of NHS and academic research centres
- World-class clinical, scientific and operational expertise
- A broad UK patient population
- A streamlined path from lab to clinic
- Regulatory engagement shaping future policy



World-class clinical and scientific expertise

	Adult Network		Paediatric Network		
Belfast	Vicky Coyle	Daniel Longley			
Birmingham	Dion Morton	Gary Middleton	Bruce Morland	Pamela Kearns	Andrew Peet
Bristol			Helen Rees		
Cambridge	Duncan Jodrell		Amos Burke	Richard Gilbertson	
Cardiff	John Chester	Oliver Ottmann			
Edinburgh	David Cameron	Stefan Symeonides			
Glasgow	Jeff Evans	Richard Wilson	Milind Ronghe		
London - Barts	Peter Schmid	Thomas Powles			
London - ICR	Johann Sebastian de Bono	Udai Banerji	Lynley Marshall	Louis Chesler	
London - Imperial	Michael Seckl	Eric Aboagye			
London - Kings Health Partners	James Spicer	Anand Purushotham			
London - UCL	Tim Meyer	John Hartley	Darren Hargrave	John Anderson	
Leeds			Martin Elliott		
Leicester	Anne Thomas	Karen Brown			
Liverpool	Daniel Palmer		Lisa Howell		
Manchester	Natalie Cook	Caroline Dive	Guy Makin		
Newcastle	Ruth Plummer	Yvette Drew	Quentin Campbell-Hewson	Gareth Veal	Deborah Tweedle
Oxford	Sarah Blagden				
Sheffield	Sarah Danson	Ingunn Holen			
Southampton	Andrew Davies		Juliet Gray		


Our impact



A streamlined operational path from lab to clinic

The ECMC Programme Office

- Co-ordinated protocol development, feasibility and placement offering
- Enhanced patient referral capabilities
- Facilitated Network Expert Groups driving best practice, innovation and development:
 - Research Nurse
 - Investigator Training
 - Quality Assurance Translational Science
 - UK Therapeutic Cancer Prevention Network



PARTNERING TO DRIVE NOVEL COMBINATION THERAPIES

- **CANCER RESEARCH UK** – largest non-government funder of cancer research in the world.
- **QUALITY** - The CRUK Combinations Alliance provides a straightforward mechanism for companies to execute high quality off-critical path Phase Ib/IIa trials with other novel company drugs (from our Alliance partners) or existing therapies, including radiotherapy.
- **WORLD CLASS EXPERTISE** – Ideas are generated and trials are conducted through the Experimental Cancer Medicine Centre network
- **INFRASTRUCTURE** – A model of working with one early phase expert network, supported by CRUK funding and administrative support

CURRENT PORTFOLIO

600+

PATIENTS ENROLLED

50

DRUGS OFFERED



TO FIND OUT MORE:
www.ecmcnetwork/ca
combinationsalliance.org.uk

Case Study: TAX-TORC

- Investigator-sponsored Phase I
- mTORC1/2 inhibitor+paclitaxel in solid tumours with NSCLC and HGSOc expansion
- Study approval to open: 12 months
- Network-wide engagement: 9 ECMC centres
- Adaptive trial design facilitated rapid translation of emerging efficacy into additional expansion arm
- Phase II (Octopus) delivered through NIHR network



The image is a screenshot of a BBC News article. At the top, the BBC logo is visible on the left, and 'Sign in' and 'More' options are on the right. Below the logo is a red navigation bar with the word 'NEWS' in white. Underneath this bar is a secondary navigation bar with links for 'Home', 'UK', 'World', 'Business', 'Politics', 'Tech', 'Science', 'Health', and 'More'. The article is categorized under 'Health'. The main headline reads 'Drug cocktail can 'shrink cancer tumours''. The author is identified as 'By Nazima Pathan, Science fellow, BBC News'. The date is '22 August 2018'. There are social media sharing icons for Facebook, WhatsApp, Twitter, Email, and a general 'Share' button. Below the text is a photograph showing a person's bare midsection with their hands resting on their abdomen. A small 'GETTY IMAGES' watermark is in the bottom right corner of the photo. Below the photo, a caption states: 'Most of the women with ovarian cancer in the study saw their tumours shrink'.

Patients with advanced ovarian or lung cancer could benefit from a new drug combination that might give them more months of life, researchers say.

They tested the therapy on 25 women with high-grade serous ovarian cancer and 40 patients with squamous non-small cell lung cancer.

Contact us

Programme Office

W: www.ecmcnetwork.org.uk

E: ECMCadmin@cancer.org.uk

Combinations Alliance

W: www.ecmcnetwork.org.uk/ca

E: combinationsalliance@cancer.org.uk